Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ICOA holding here, no one wants to sell cheap shares, this has tons of upside
ICOA moving easily, had big bounce to .0033 on nothing, this has tons of upside, down way too much, cathc the pullbacks, this should move much higher
ICOA moving! now .0026 x .0027
news is never an issue when these drop, it is very common for post r/s stocks to drop,and when they drop hard and fast and way too much, that's when you buy...yes, still could go lower, but this is a good start at a bottom drop
ICOA down too much, should be at .50 after 1:5000 rs in May!!!, 'd' came off beginning of june, this will move
ICOA had r/s of 1:5000 May 5 2010, then had 'd' on end which came off june 1st, trying to find the bottom..this may be it, watching
THIS IS DOWN WAY TOO MUCH AFTER R/S!!!...should be at .50!!
NSM.v what a dumpathon going on here, lots absored at .08, lod so far, will this go lower or bounce..hmmm
NSM.v taking big dump on news, down 42%, GPG.V bouncing today
GPG.v big dump, down 33% so far
SAM.to down 26% on news
Ya, the data feed problems are another issue that constantly seems to be going wrong, and my alerts not going off is really hurting my trading, and they just don't care! really bugs me, im tired of having to constantly complain about somethign for months before they fix it, i know its going to be something that has to do with their system. I do have a ton of alerts, but i redueced them significantly and still same problem. I'm paying them money but yet i can't make any because they aren't performing properly yet agian.
tired!!!
thanks for your reply
Equityfeed giving me problems again, my alerts that i set before today do not go off, so I miss everything. Only If I place the alerts today, they get triggered. Equityfeed doesn't seem to give a crap when I have complained about it several times, they keep saying it must be me, but I don't think so. They have told me that many times in the past that problems had to do with my pc, and most of the time they were wrong. So I don't believe a word they say anymore. Now, they just ignore my emails, nice of them.
anyone else having any issues with equityfeed?
Today was the warm up, its gearing up, lots of pullbacks with this stock
SUV.v big dump, to .025, one huge trade, now .025 x .03, maybe bounce to .035 or .04?
CDOI strong bid support, pm next leg coming
Thanks!!!
SCOXQ down 68% for no apparent reason..bounce play
SCOXQ down 68% for no apparent reason..bounce play
Ya me too, not sure why this drop, cant find any reason.
SCOXQ just dropped hard for no apparent reason, it doesnt look like its being delisted, not on daily list and no filing i can see says that..looks like a panic drop
Ahhh, yes, that thought crossed my mind too. I often have to compete with this Anonymous, they are very fast and start loading on the bid, it often seems though that there is a few traders working together because they place orders (multiple) way too fast..they are literally everywhere at once, I'm really sick of fighting with them lol. I even recognize their style, so it peeves me off when I see them and know it's this secret team controlling stocks.
Thanks for your research on this sno43wolf, i also tried searching the net for some info but found nothing. Ah well, a manipulated market by insiders, who would have guessed, lol.
have a great weekend :)
Hey anyone know who 1 Anonymous is on L2, this guy or company or team is absolutley everywhere, I'm always fighting with them for the bid, it's unbelievable. They pretty much monopolize the bottoms on stocks, you see them pop up everywhere when stocks are dropping. It looks like a team, I really hate their guts, lol..who the heck are they/it? Anyone know anything?
EAG.v doing nicely, had news yesterday
EWD.v down large on news, halt removed earlier today.
ya...I wonder if they will even bother, they seem to hate us Canadians lol, we're always on the bottom of the list!
Ya, stockcharts really sucks though, it seems every few days I have to send in a request for a CAD ticker as they don't have the charts, they miss a lot of them...anyway, I just sent a request in for it, but if you send in a request too, it might help, sometimes they ignore my requests for months until the stock has a run, then they will add it only when I request it again.
PKP.v big tank on news:
-----------------------------
PetroKamchatka to abandon Chernorechenskaya 1P well
2010-05-31 09:18 ET - News Release
Mr. Graeme Phipps reports
PETROKAMCHATKA PLC (TSXV: PKP) ANNOUNCES ABANDONMENT OF CHERNORECHENSKAYA EXPLORATION WELL
PetroKamchatka PLC has ceased drilling operations at the Chernorechenskaya 1P exploration well in Kamchatka, Russia, and plans to abandon the well. The well reached a total depth of 2,596 metres in basement rocks on the structure without encountering the target Snatol formation sandstones. Wireline logging operations will now be undertaken for confirmation. The company will evaluate the well results to date and use the information to determine future drilling plans.
GAP.V and SSS.v both inching higher from their drops I mentioned last week
SSS.v seems to have found bottom at .07 and now turning after huge drop on news. GAP.v was doing well too and just dropped here when filings came out, but I believe this will go back up as it had great cancer news that caused its run, the good news had taken it down of course..sell the news, lol. GAP.V get the .15's if u can, hopefully won't drop lower, but seems to have so far established its base
GAP.vn hit nlod of .15..this thing has to bounce, lol..maybe june?
TH.TO down large today too, good vol, nice intraday bounces, don't know why its down.
SSS.vn trying to bounce here during lunch, just touched .1, hit lod of .08!!! i think this is too much and being taken down, market again not helping. BUt, ke lows, as this stock will run on good news, whenever that may be and when it has been sitting low for awhile...GL!
Stem Cell's NTx-265 no different than placebo in trial
2010-05-25 07:18 ET - News Release
Dr. Alan Moore reports
STEM CELL THERAPEUTICS CORP. ANNOUNCES TOP-LINE RESULTS FOR THE MODIFIED REGENESIS PHASE IIB STROKE TRIAL
Stem Cell Therapeutics Corp. has released the top-line results for the modified Regenesis-phase IIb stroke trial. The modified Regenesis-phase IIb trial, a placebo controlled, double blinded, 3:1 randomized clinical study, enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. SCT reports that the top-line primary endpoint results for this Phase IIb clinical trial of NTx-265 in acute stroke showed that there was substantial improvement in the primary endpoint absolute change in NIHSS in both placebo treated patients and those receiving NTx-265 with no statistical differences between the groups.
"The profile and magnitude of the placebo response is extremely surprising and merits further examination" said Dr. Alan Moore, CEO and President of Stem Cell Therapeutics. "We are currently conducting a validation review process of the full trial. We expect to report on the outcome of this within the next 2-3 weeks, together with results from a number of secondary endpoints such as modified Rankin and Barthel index, which may provide an alternative to NIHSS as a pathway forwards."
The results show that NTx-265 was well tolerated in treated patients with no adverse affect on mortality. Of the 96 patients enrolled in the trial, 72 patients were administered a course of NTx-265, sequential administration of human chorionic gandotropin (hCG) followed by erythropoietin (EPO), with the first dose at 24-48 hours after stroke onset while 24 patients were treated with placebo. All patients were then monitored for 90 days. The top-line data show that the NTxAtrademark-265 treated group showed a drop of 6.3 +/- 0.5 NIHSS compared to placebo drop of 7.3 +/- 0.9 NIHSS. This difference was not statistically significant. Additionally, none of the individual dose groups showed a statistically significant effect compared to placebo.
SSS.Vn down 77% on news!!! i think this is too dramatic a drop
GAP.vn and AFA.v may have found their bottoms and could be inching higher over next week or 2, keep eye on them. Now if only TDW could get their platforms to work properly and reflect accurate data, i might actually be able to make some money..shheeessshhh..as if it's not hard enough to trade with the market behaving the way it is, I have to struggle wtih contstant tech issues..thanks TDW!
KRI.TO down huge on news, halt just lifted a some minutes ago!!!
I am so peeved at this!! I had tried to buy the drop at .235, my order was next in line, when they halted it!!! dang, it would have been so pretty!!
Yes, the market is definitely retracting, but whenever there is a big retracement a bounce is in store of course. GAP.v also does characteristicly do big pullbacks, but the market sure isn't helping it, but i believe it will bounce...now which support level will it bounce from, I guess the market will decide that. I've got orders in and ready to pick some up, maybe .16 is the low..we'll see
GAP.V was taken down after great news, today more news, should bounce some
PharmaGap examines effect of drug on ovarian cancer
2010-05-19 08:44 ET - News Release
Mr. Robert McInnis reports
PHARMAGAP ANNOUNCES RESULTS OF IN VIVO STUDY AT THE OTTAWA HOSPITAL RESEARCH INSTITUTE TESTING THE EFFECT OF THE COMPANY'S LEAD DRUG ON OVARIAN CANCER
PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) ("PharmaGap" or "the Company") today released initial testing results for PharmaGap's cancer drug GAP-107B8. Led by Dr. Barbara Vanderhyden, Ottawa Hospital Research Institute ("OHRI") researchers showed significant effect of GAP-107B8 in reducing tumours in mice, with no signs of toxicity. Dr. Vanderhyden stated "We are very pleased with these initial results that indicate GAP-107B8 is showing therapeutic efficacy against ovarian cancer cells implanted in mice and allowed to grow tumours. The success rate of curing women with ovarian cancer using currently available therapies is still very low, and so the identification of a possible new treatment is exciting and warrants more investigation. We are looking forward to continue working with PharmaGap on this exciting drug program."
In these tests, the two groups of mice (21 in total) were injected subcutaneously with two different ovarian cancer cell lines, and tumours were allowed to establish and grow until reaching 200 cubic millimeters in size before intra-tumoural treatment with GAP-107B8. The two human ovarian cell lines used were HEY cells and A2780cp cells. Both cell lines model aggressive human ovarian cancer in immunocompromised mice and have shown strong susceptibility to GAP-107B8 in previous in vitro testing at OHRI. The A2780cp cell line is a cisplatin/carboplatin-resistant cell line. Carboplatin forms part of the current standard of care for treatment of ovarian cancer. Recently announced results from testing at the National Cancer Institute in Bethesda MD also showed that 7 different ovarian cancer cell lines were highly susceptible to GAP-107B8.
Over the course of the experiment, GAP-107B8 caused a 45% reduction in average tumour size in the A2780cp-derived tumours (at a dose of 20 mg/kg), and 75% in the HEY-derived tumours (at a dose of 40 mg/kg).
Additional in vivo testing is currently underway, and a more robust study in mice using ovarian cancers at the OHRI will be based on information learned from these initial pilot studies and on pharmacokinetics data currently being generated by PharmaGap. This larger study is expected to begin this summer.
Dr. Vanderhyden is a Senior Scientist, Cancer Therapeutics at the Ottawa Hospital Research Institute and a Professor in the Departments of Cellular & Molecular Medicine and Obstetrics & Gynecology at the University of Ottawa. She holds the Corinne Boyer Chair in Ovarian Cancer Research. She has published over 60 peer-reviewed journal papers primarily in the area of ovarian cancer and collaborates extensively with many pharmaceutical and biotechnology companies focused on the development of therapies for ovarian cancer.
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the University's Faculties of Medicine and Health Sciences. The OHRI includes more than 1,500 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. www.ohri.ca
GAP.v dropped to .19 after open, now at .22, broke the .215 res...looking very nice, even with the market blood red again
yes, i agree, either today or tomorrow, might touch .175, would be a great buy opp, or we will see if today was the low. The red market didn't help matters, lol.